Dr. Mark T. Reding, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MN license 37501 -
Internal Medicine Physician
MN license 37501
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
- M Health Fairview Southdale Hospital Edina, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 114
- Services billed
- 186
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 50 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xarelto (rivaroxaban) Other prescribers in Minneapolis, MN | 57 |
| Warfarin Sodium Other prescribers in Minneapolis, MN | 56 |
| Oxycodone Hcl Other prescribers in Minneapolis, MN | 56 |
| Eliquis (apixaban) Other prescribers in Minneapolis, MN | 49 |
| Retacrit (epoetin alfa-epbx) | 33 |
| Oxycontin (oxycodone hcl) Other prescribers in Minneapolis, MN | 30 |
| Fondaparinux Sodium | 29 |
| Jantoven (warfarin sodium) Other prescribers in Minneapolis, MN | 23 |
| Celecoxib Other prescribers in Minneapolis, MN | 18 |
| Tranexamic Acid | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 43 payments worth $70,448 in total to this clinician.
| Sanofi US Services Inc. | $19,805 |
|---|---|
| Hema Biologics, LLC | $18,164 |
| Novo Nordisk Inc | $10,730 |
| Genentech USA, Inc. | $9,364 |
| Kedrion Biopharma, Inc. | $4,200 |
| Genzyme Corporation | $4,159 |
| Bayer HealthCare Pharmaceuticals Inc. | $1,636 |
| Pfizer Inc. | $1,250 |
| Consulting Fee | $46,796 |
|---|---|
| Honoraria | $15,500 |
| Travel and Lodging | $3,436 |
| Compensation for services other than consulting (speaking, faculty) | $3,382 |
| Food and Beverage | $1,335 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Nov 7, 2025 | Consulting Fee ALTUVIIIO · Hematology | $19,805 |
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $9,006 |
| Genentech USA, Inc. Sep 26, 2025 | Consulting Fee Hemlibra · Hematology | $6,970 |
| Hema Biologics, LLC Jun 22, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,500 |
| Hema Biologics, LLC May 7, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Hema Biologics, LLC Nov 8, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Kedrion Biopharma, Inc. Sep 28, 2025 | Consulting Fee Ryplazim · PLASMINOGEN | $4,200 |
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,632 |
| Genentech USA, Inc. Dec 5, 2025 | Consulting Fee Hemlibra · Hematology | $2,050 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 23, 2025 | Consulting Fee Jivi · Hematology | $1,598 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Dec 5, 2025 | Consulting Fee Hemlibra · Hematology | $2,050 |
| Genentech, Inc. Nov 25, 2025 | Consulting Fee Hemlibra · Hematology | $1,140 |
| Hema Biologics, LLC Nov 10, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to DALLAS, TX · in-kind | $259 |
| Hema Biologics, LLC Nov 10, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to DALLAS, TX · in-kind | $33.67 |
| Hema Biologics, LLC Nov 8, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Sanofi US Services Inc. Nov 7, 2025 | Consulting Fee ALTUVIIIO · Hematology | $19,805 |
| Pfizer Inc. Oct 31, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,250 |
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,632 |
| Hema Biologics, LLC Oct 28, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to DALLAS, TX · in-kind | $376 |
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $9,006 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $610 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $419 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $204 |
| Kedrion Biopharma, Inc. Sep 28, 2025 | Consulting Fee Ryplazim · PLASMINOGEN | $4,200 |
| Genentech USA, Inc. Sep 26, 2025 | Consulting Fee Hemlibra · Hematology | $6,970 |
| Genentech USA, Inc. Sep 26, 2025 | Travel and Lodging Hemlibra · Hematology · travel to Rosemont, IL | $52.56 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 23, 2025 | Consulting Fee Jivi · Hematology | $1,598 |
| Hema Biologics, LLC Jun 22, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,500 |
| Genzyme Corporation May 27, 2025 | Consulting Fee | $777 |
| Hema Biologics, LLC May 7, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $5,000 |
| Hema Biologics, LLC May 7, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to LOUISVILLE, KY · in-kind | $332 |
| Hema Biologics, LLC May 7, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to LOUISVILLE, KY · in-kind | $58.64 |
| Hema Biologics, LLC May 6, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to LOUISVILLE, KY | $94.27 |
| Hema Biologics, LLC Apr 28, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to LOUISVILLE, KY · in-kind | $997 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $40,770 in research payments for these studies, mostly to the institutions running them.
- BAY 949027, PREDICT Study A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.